Capricor Therapeutics, Inc. (CAPR) – What Are Researchers Thinking About This Stock?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned an average rating of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $30.25.

A number of equities analysts recently weighed in on the stock. LADENBURG THALM/SH SH lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a research report on Thursday, October 8th. Finally, Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in CAPR. KBC Group NV bought a new position in Capricor Therapeutics in the 1st quarter worth about $44,000. Activest Wealth Management increased its position in shares of Capricor Therapeutics by 100.0% during the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 2,000 shares during the period. Quantinno Capital Management LP increased its position in shares of Capricor Therapeutics by 16.8% during the first quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company’s stock worth $440,000 after acquiring an additional 2,083 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 21.2% during the third quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 3,036 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its stake in shares of Capricor Therapeutics by 13.2% during the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock valued at $1,104,000 after acquiring an additional 4,240 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 4.7%

NASDAQ CAPR opened at $9.00 on Friday. The stock’s 50 day moving average is $8.08 and its 200 day moving average is $20.20. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The stock has a market cap of $523.25 million, a PE ratio of -3.67 and a beta of 0.80.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). On average, analysts forecast that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.